Recently, the serial work suggested PDE4 could be a promising therapeutic target for various diseases, such as nephrotic syndrome [43], acute myeloid leukemia [44], idiopathic pulmonary fibrosis [45], heart failure [46], and colitis [8]. Here, PDE4A is linked to pulmonary fibrosis.